Cardiology · Obstetrics & Gynecology · General Practice · 4 h ago
AHA-led statement proposes life-stage framework for women’s cardiovascular care
A multisociety scientific statement introduces four female life stages to organize cardiovascular prevention and management across the lifespan. It also treats pregnancy as a modifying event that may reveal or increase cardiovascular risk.
- Framework defines four female life stages for cardiovascular care.
- Pregnancy may reveal or modify cardiovascular risk.
- Statement calls for coordinated care and improved clinician education.
The American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine convened a multisociety advisory group to address fragmented care and inconsistent guidance for girls and women. The scientific statement crosswalks major society guidelines and synthesizes evidence on hormonal, psychosocial, and cardiovascular health.
It proposes a Female Life Stage construct with four stages: perimenarche, ovarian cycling, perimenopause, and postmenopause. Pregnancy is included as a distinct modifying life event, during which cardiovascular risk may emerge or be unmasked, including through adverse pregnancy outcomes. The authors provide consensus-based screening, prevention, and treatment considerations for each stage and health domain, and call for improved clinical workflows, clinician education, and research on evidence and implementation gaps.
The statement offers a framework for coordinating care across specialties rather than reporting results from a new clinical study. The supplied abstract does not provide specific recommendations or supporting evidence details; clinicians should consult the full statement for stage-specific guidance.
In practice
The statement proposes organizing cardiovascular prevention and management around four female life stages, with pregnancy considered a modifying event that may reveal or increase risk. This may help clinicians coordinate attention to hormonal, psychosocial, and cardiovascular factors across specialties. It is consensus-based guidance, not a report of a new clinical trial; the supplied abstract does not detail specific stage-based actions or evidence strength. Clinicians should consult the full statement before applying particular screening or treatment recommendations.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Circulation: Consensus Guidance for the Female-Specific Prevention and Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.